‘This latest patent adds to Prescient’s considerable patent estate, and provides Prescient with intellectual property protection covering its lead compound for the treatment of patients with cancer that overexpresses Akt.’
Excellent addition to the patent ‘estate.’
Commendable behind the scenes achievement,
as now almost expected by this blue chip team.
Well done.
